New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
05:26 EDTAMPEAmpio announces active IND for Optina for treatment of DME
Ampio Pharmaceuticals announced that the FDA has accepted the company's IND for Optina for the treatment of Diabetic Macular Edema, or DME. Ampio plans to commence enrollment in a clinical trial in Q1. The FDA granted Optina 505 b 2 status in July, 2012. Drugs designated under this pathway can be approved on a single trial.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
08:04 EDTAMPEAmpio subsidiary secures European distribution for RedoxSYS diagnostic system
Ampio subsidiary Luoxis Diagnostics has secured long-term agreements with European distributors Eurobio, Una Health Limited, and THP Medical, to offer Luoxis' RedoxSYS Diagnostic System to academic and pharma-based research centers within their respective territories. RedoxSYS is a diagnostic platform and robust research tool capable of measuring oxidation-reduction potential in the body in response to injury, illness, or stress. Eurobio was granted territorial rights to offer RedoxSYS to institutions based in France and Switzerland, while Una Health Limited and THP Medical were granted territorial rights to the U.K. and Austria, respectively. These are multi-year agreements with the option to renew at the 3-5 year mark.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use